Teva Pharmaceutical Industries

  • Is This Healthcare Stock Underrated?

    By Leo Sun - August 16, 2013 | Tickers: ELN, GSK, JNJ, PRGO, TEVA

    Shares of Perrigo Company (NYSE: PRGO), one of the world’s largest healthcare suppliers, slid with the broader market on August 15, after the company reported fourth quarter earnings that topped analyst estimates but missed revenue forecasts. Over the past month, Perrigo has drawn a lot of criticism for its $8.6 billion takeover of Irish pharmaceutical Elan Corporation (NYSE: ELN), which redcued its corporate tax rate by moving its more »

  • A Winner and 2 Losers in the Battle Over Multiple Sclerosis Treatments

    By Leo Sun - August 13, 2013 | Tickers: BIIB, NVS, TEVA

    There are several major players engaged in multiple sclerosis (MS) treatments. Orally administered treatments have been rapidly replacing older, interferon-based injections, and all eyes were on Biogen Idec’s (NASDAQ: BIIB) newest oral MS treatment, Tecfidera, which was launched in April. At the time, Biogen hadn’t reported its first quarter of Tecfidera sales yet, and investors were still waiting to see if Tecfidera would be the industry changing drug more »

  • Obamacare and Generic Pharmaceuticals

    By Daniel Jennings - August 9, 2013 | Tickers: ACT, PRGO, TEVA

    Will generic pharmaceutical makers like Teva Pharmaceutical (NYSE: TEVA) and Perrigo (NYSE: PRGO) continue to be a value play after Obamacare kicks in next year?

    That’s a fair question to ask because some of these companies seem to be on shaky ground now. Revenues and free cash flow have been falling without Obamacare.

    Teva saw its revenues fall by 8% in the fourth quarter of 2012 and a pretty more »

  • A Closer Look at Pfizer’s Three-Way Split

    By Leo Sun - August 7, 2013 | Tickers: ABT, ACT, MRK, PFE, TEVA

    Last week, pharma giant Pfizer (NYSE: PFE) announced that it was planning to split the company into three businesses -- a move that had been long anticipated by analysts and investors alike. Although this move streamlines the company’s core businesses’ financials, does it change anything for investors?

    Prelude to a spin-off

    In its first business segment led by Geno Germano, Pfizer intends to group immunology and metabolic treatments together with more »

  • Can the Rise of the Global Old Help You Retire?

    By Paul Sangrey - August 6, 2013 | Tickers: MYL, NVS, PFE, TEVA

    Big Pharma is in trouble. U.S. pharmaceutical revenue fell for the first time on record last year because so many drugs came off of their patents, what was called as the patent cliff. In real terms, revenue fell by 3.5% according to the New York Times . Furthermore, another smaller but still notable patent cliff is coming in 2015.

    So, at first glance, now doesn't seem to be more »

  • A Safe Investment With Growth Promise

    By Mohsin Saeed - August 6, 2013 | Tickers: AZN, PFE, TEVA

    Teva Pharmaceuticals (NYSE: TEVA) has been stuck is share purgatory for a number of years. There have been no capital gains, and the dividend yield is mediocre at best. This has forced Teva to undertake a radical overhaul of its business strategy.

    The recently-released second quarter results did not reflect the effects of this improved business strategy. Teva barely managed to meet expectations, with margins and revenues below expectations.

    However more »

  • Out With the Old, In With the New in Treating MS

    By Ryan Guenette - July 31, 2013 | Tickers: BIIB, NVS, PFE, SNY, TEVA

    Hidden beneath all the numbers and metrics in Biogen Idec's (NASDAQ: BIIB) recent earnings report  is a key confirmation of a shifting market in the treatment of multiple sclerosis. This alteration could yield billions of dollars for companies positioned to take advantage of it. 

    What Happened

    On July 25, Biogen reported second-quarter financial results. Earnings of $2.30 per share and revenue of $1.7 billion both trumped estimates more »

  • Conquer the Generic Drug Market With Taro

    By Jaiyant Cavale - July 31, 2013 | Tickers: ACT, TARO, TEVA

    Taro Pharmaceutical Industries (NYSE: TARO) hardly gets the attention it deserves. The Israel-based generic-pharmaceutical manufacturer supplies in Israel, the U.S., Canada, the U.K., Ireland and in a few other countries. The company was listed on New York Stock Exchange Euronext in March 2012 and is currently one of the best pharmaceutical companies to invest in. In this article, I shall profile this relatively unknown company and discuss why more »

  • Is Teva Making a Comeback?

    By Lior Cohen - July 23, 2013 | Tickers: MRK, PFE, TEVA

    The recent rally in shares of Teva Pharmaceutical Industries (NYSE: TEVA) may suggest investors are regaining some confidence in this pharmaceutical manufacturer. Will Teva’s upcoming second-quarter financial report, which will come out on August 1, show signs of recovery? Will it surprise investors? Is it worth having this giant generic-drug manufacturer in your portfolio?

    Generic medicine sales are falling

    One of the biggest hits Teva has taken so far more »

  • Generics Set to Soar

    By Marshall Hargrave - July 22, 2013 | Tickers: ACT, HSP, MYL, TEVA

    IMS Health pegs the worldwide generic drug market at an impressive $240 billion, which should only grow over the long-term as a large number of branded drugs lose patent protection -- pushing the total generic drug market to over $420 billion in 2016. 

    Other key factors driving generic market growth will be a rapidly aging population and the healthcare reform in he U.S., which will give more people access to more »

  • Antares Pharma: A Critical Look

    By Ali Yasar - July 5, 2013 | Tickers: ATRS, PFE, TEVA

    Recently, I enjoyed an article contributed by Adam Feuerstein ("AF article") regarding Antares Pharma (NASDAQ: ATRS) and its transformational product Otrexup. Here, I would like to present my views on the following items debated in the AF article: (1) sufficiency of data submitted to FDA, (2) marketability and sales of Otrexup, and (3) Antares’s market capitalization and its buyout potential.

    Otrexup is a drug-device combination currently seeking FDA approval more »

  • Amgen's Future Is Bright

    By Terry Chrisomalis - June 29, 2013 | Tickers: AMGN, PFE, TEVA

    Amgen (NASDAQ: AMGN) has gone up a lot in share price over the last few years. Amgen has climbed up 91% over the past three years, leaving long-term investors with a lot of gains. In the same time period the Dow Jones has only gone up 64%. Despite the big run, the company can still see its share price rise higher in the coming years. The company has been known more »

  • An Insider and His Wife Are Buying This Pharma Stock

    By Meena Krishnamsetty - June 28, 2013 | Tickers: MRK, NVS, REGN, TEVA, VRX

    According to a filing with the SEC, between June 11 and June 12, Valeant Pharmaceuticals (NYSE: VRX) Board member Lloyd Segal directly purchased 2,800 shares of the stock at an average price of $83.85 per share. This gave him a total of slightly more than 21,000 shares of the stock, and came at the same time as his wife purchased close to 400 shares of Valeant.

    We more »

  • Hedge Fund Brahman Capital Bets Big on This Pharma Stock

    By Meena Krishnamsetty - June 28, 2013 | Tickers: ABT, ENDP, GILD, TEVA

    A 13G filed with the SEC has disclosed that Brahman Capital, a hedge fund managed by Peter Hochfelder and his team, owns 6.3 million shares of Endo Health Solutions (NASDAQ: ENDP), a $4.3 billion market cap pharmaceutical company.

    We track quarterly 13F filings from hedge funds such as Brahman as part of our work researching investment strategies (we have found, for example, that the most popular small cap more »

  • 3 Intriguing Plays That This Hedge Fund Is Focusing On

    By Meena Krishnamsetty - June 27, 2013 | Tickers: INFY, MPC, TEVA

    At Insider Monkey, we’ve reported on quite a bit of first quarter 13F filings thus far, but one hedge fund we haven’t taken a look at is Bernard Horn's Polaris Capital Management. Established in 1995, Polaris is an equity-focused investment firm with a penchant for value, and it recently reported that it manages over $4 billion in assets. It’s always important to track hedge fund sentiment more »

  • This Pharmaceutical Stock Promises Robust Returns

    By Kiran Gulati - June 21, 2013 | Tickers: ABT, TEVA, VRX

    The healthcare sector has always been a subject of great interest to investors and analysts alike. With the rise of sedentary lifestyles and increasing stress levels across demographics, the healthcare sector has a huge market to cater to.

    Valeant Pharmaceuticals (NYSE: VRX) is a fast growing company in dermatology, ophthalmology and neurology. Over the years, Valeant has developed a disparate product portfolio comprising of prescription drugs, branded generics and Over more »

  • This Promising Biotech Can Triple

    By Mohsin Saeed - June 19, 2013 | Tickers: ONCY, PFE, TEVA

    Cancer is one of the deadliest challenges that humans face today. Different forms of cancer have taken millions of lives all around the world. According to studies, every year approximately 7.5 million patients are diagnosed with cancer. This  presents a massive commercial opportunity for healthcare companies making anti-cancer drugs.

    Recent studies have revealed that viruses are the best way to treat cancers. Some specific viruses attack the cancer cells more »

  • Can Avastin’s Shortcomings Open the Door for Del Mar Pharmaceuticals?

    By Craig Keolanui - June 14, 2013 | Tickers: MRK, PPHM, RHHBY, TEVA

    The effectiveness of Genentech and Roche's (RHHBY.OB) glioblastoma multiforme (GBM) treatment, Avastin, has recently been challenged raising concerns from physicians and patients alike that a huge void in patient care can develop if the FDA decides to revoke Avastin's approval for treating GBM. GBM is one of the hardest indications of cancer to treat with a median survival of about 4.5 months without treatment and less more »

  • Undervalued Teva Must Enter New Markets

    By David Gould - June 12, 2013 | Tickers: JNJ, MYL, TEVA

    Generic producers are often regarded as the safer players within BioPharma. They take existing drugs that have fallen off patents, tweak them a bit, and release a product into the market. R&D expenses are kept low, and business is relatively predictable.

    Similarly, medical device companies have lower risk profiles by virtue of their more predictable operating model. However, they both have experienced their own problems and are not resting more »

  • Will This Company Dominate the Multiple Sclerosis Market?

    By Kanak Kanti - June 12, 2013 | Tickers: BAYRY.PK, BIIB, TEVA

    With one product already on the market, one recently approved and four more in various stages of clinical development, Biogen Idec (NASDAQ: BIIB) has a very strong presence in the multiple sclerosis space. Multiple sclerosis is a debilitating disease that affects 2.5 million people worldwide, and 400,000 Americans annually, according to WebMD.

    Making Biogen Idec's position even stronger, the company recently submitted a biologics license application more »

  • Page 1 of 7